The Series A financing round of 15 million was completed by YGION, a company dedicated to developing individualized neoantigen-based cancer vaccines.
YGION's high-profile team of experienced biotech veterans and entrepreneurs are focused on developing individualized "plug-and-play" cancer vaccines through a proprietary suite of technologies.
YGION is on the verge of a breakthrough in individualized cancer treatments and we are grateful for the support.
"We are confident that with our technology, we can realize the promise of simple, safe and effective cancer vaccines," said Dr. Geert Mudde, Chief Technology Officer of YGION.
YGION's lead program is currently in development.
About YGION Biomedical.
YGION is committed to realizing individualized immunotherapies against cancer and is located in Vienna, Austria.
Contact.
There is a Chief Business Officer for YGION Biomedical.
There is a logo for ygionbiomedicalgmbH.
YGION Biomedical ist an sterreichisches Biotechnologieunternehmen, das individualisierte Krebsimmuntherapienwickelt.
YGION Biomedical is a société that has a base de néo-antignes.

Source prnewswire